On 14 September 2026 the FDA recorded a supplement to abbreviated new drug application 206741, a generic itraconazole held by Alembic, an Indian manufacturer.
The record does not state what the supplement changed. Supplements to generic applications are usually manufacturing, labelling or packaging updates that keep the product in line with the reference drug. This is not a new indication and not a safety communication.
It is noted here because itraconazole is widely prescribed in India for dermatophytosis and other fungal infections, and Indian manufacturers supply much of the global generic market. Nothing in the record calls for a change in prescribing.
- No prescribing change follows from this supplement; the record gives no clinical detail.
- A supplement to a generic application is not a new indication or a safety warning.
- Itraconazole absorption varies between formulations; keep a patient on the same product where possible.
- Check interactions before prescribing itraconazole; it is a strong CYP3A4 inhibitor.
Why it matters
It is routine generic maintenance for a drug Indian clinicians prescribe heavily, not a safety finding.
Don't overread it
A licence supplement is not a new indication, and the record does not say what changed.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for infectious diseases, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free